Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Cardiovascular Disorders

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

A comparative study of time-specific oxidative stress after acute myocardial infarction in patients with and without diabetes mellitus

  • Daisuke Kitano1,
  • Tadateru Takayama1,
  • Koichi Nagashima1,
  • Masafumi Akabane1,
  • Kimie Okubo1,
  • Takafumi Hiro1 and
  • Atsushi Hirayama1Email author
BMC Cardiovascular DisordersBMC series – open, inclusive and trusted201616:102

https://doi.org/10.1186/s12872-016-0259-6

Received: 21 July 2015

Accepted: 29 April 2016

Published: 23 May 2016

Abstract

Background

Oxidative stress is involved in the initiation and progression of atherosclerosis, and hyperglycemia is known to increase oxidative stress, which injures the endothelium and accelerates atherosclerosis. To clarify the relation between oxidative stress, diabetes mellitus (DM), and acute myocardial infarction (AMI), we evaluated and compared time-specific oxidative stress after AMI in patients with and without DM by simple measurement of derivatives of reactive oxygen metabolites (d-ROMs) levels as indices of reactive oxygen species production.

Methods

Sixty-eight AMI patients were enrolled (34 non-DM patients and 34 DM patients). Using the FRAS4 free radical analytical system, we measured d-ROMs levels in each patient at two time points: 1 and 2 weeks after AMI onset.

Results

d-ROM levels decreased significantly between week 1 and week 2 (from 475.4 ± 119.4 U.CARR to 367.7 ± 87.9 U.CARR, p < 0.001) in the non-DM patients but did not change in the DM patients (from 463.1 ± 109.3 U.CARR to 461.7 ± 126.8 U.CARR, p = 0.819). Moreover, significant correlation was found in the total patient group between d-ROMs levels at 1 week and N-terminal prohormone of brain natriuretic peptide (r = 0.376, p = 0.041) and between d-ROM levels at 2 weeks and 2-hour oral glucose tolerance test glucose levels (r = 0.434, p < 0.001).

Conclusions

Exposure to oxidative stress is greater in AMI patients with DM than AMI patients without DM. Our study results suggest that it is the continuous hyperglycemia that increases oxidative stress in these patients, causing endothelial dysfunction and accelerating atherosclerosis. However, long-term follow up study is needed to assess whether the increased oxidative stress affects patient outcomes.

Keywords

Derivatives of reactive oxygen metaboliteOxidative stressAcute myocardial infarctionDiabetes mellitus

Background

Oxidative stress, which is implicated in various disorders, especially lifestyle-related diseases such as diabetes mellitus (DM), is involved in the initiation and progression of atherosclerosis [13]. Biomarkers of oxidative stress, such as serum malondialdehyde measured as thiobarbituric acid-reactive substances, oxidized low-density lipoprotein, oxidative DNA damage byproduct 8-hydroxydeoxyguanosine, and urinary 8-iso-prostaglandin-F2α, are generally measured in research laboratories [47]. Indices of antioxidant potential, especially intracellular levels of superoxide dismutase and glutathione peroxidase, are also measured [8, 9]. However, the assay methods are complex and not suitable for large-scale analysis. Simpler means of detecting reactive oxygen species (ROS) by assay of derivatives of reactive oxygen metabolites (d-ROMs) and biological antioxidant potential have been developed, and reports of these methods and studies based on these methods have been increasing [1019].

DM is a major risk factor for cardiovascular disease. Continuous hyperglycemia increases advanced glycation end products (AGEs) and induces ROS production [20]. ROS plays a pivotal role in the development of the microvascular and cardiovascular complications of DM. The increased ROS in patients with type 2 DM and metabolic syndrome is a consequence of metabolic abnormalities, including hyperglycemia, insulin resistance, hyperinsulinemia, and dyslipidemia [21], each of which contributes to mitochondrial superoxide overproduction in endothelial cells of large and small vessels as well as the myocardium [22]. The atherosclerosis is accelerated and may induce acute coronary syndrome.

Thus, we are interested in the relations between oxidative stress, DM, and acute myocardial infarction (AMI), we evaluated and compared time-specific oxidative stress after AMI in patients with and without DM by simple measurement of d-ROMs levels as indices of ROS production.

Methods

Study patients

The study involved 68 consecutive patients who had suffered an ST-elevated AMI, admitted to the coronary care unit of Nihon University Itabashi Hospital between April 2010 and March 2011, and underwent successful primary percutaneous coronary intervention (PCI). Thirty-four had type 2 DM (DM group) and 34 did not (non-DM group). Patients with severe MI; those recovering from cardiopulmonary arrest or heart failure; and those with cardiomyopathy, severe valvular disease, atrial fibrillation, chronic kidney disease requiring hemodialysis, type 1 DM, type 2 DM requiring insulin or glucagon-like peptide-1 receptor agonists treatment, collagen disease, or malignant tumor were excluded from the study. Medications patients had been taking were not changed, and anti-diabetic agents were not given during the study period. We also collected d-ROM values in stable coronary artery disease (CAD) patients without DM (n = 40) and with DM (n = 28) as reference value, they had undergone coronary stenting for stable CAD except acute coronary syndrome more than 8 months before data collection.

The study was approved by the ethics committee of Nihon University Itabashi Hospital, and written informed consent was provided by each patient for participation.

Clinical evaluation and laboratory measurements

Patients’ clinical characteristics, including age, sex, body mass index, smoking history, and history of hypertension and dyslipidemia were recorded, and blood samples were drawn 1 week after AMI onset for measurement of hemoglobin A1c (HbA1c), fasting glucose, total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, creatine phosphokinase (CPK), estimated glomerular filtration rate (eGFR), high-sensitivity C-reactive protein (hs-CRP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP). Insulin resistance was evaluated by means of homeostasis model assessment of insulin resistance (HOMA-IR), and an oral glucose tolerance test (OGTT) was given to evaluate glucose clearance.

Assay of oxidative stress

We quantified hydrogen peroxide levels by measuring d-ROMs using the FRAS4 Free Radical Analytical System (H&D srl, Parma, Italy). Hydrogen peroxides are converted into radicals that oxidize N, N-diethyl-para-phenylenediamine and can be detected spectrophotometrically with the use of an all-purpose automatic analyzer. The d-ROM levels are expressed in arbitrary units called Carratelli units (U.CARR) [10]. The normal reference level of d-ROMs is 250 to 300 U.CARR [23, 24]. We measured d-ROMs at 2 time points, 1 week and 2 weeks after AMI onset, to avoid the possible influence of AMI.

Statistical analysis

Continuous variables are expressed as mean ± SD values, and categorical variables are presented as numbers and percentages. Between-group differences were analyzed by one-way ANOVA with Tukey post-hoc honest significant difference test or by chi-square test, as appropriate. Differences between 1-week and 2-week values were analyzed by paired t-test, Wilcoxon signed-rank test, or unpaired t-test, as appropriate. Association between d-ROM levels and clinical variables was tested by linear regression analysis, and factors predictive of no or little change in the d-ROM level between 1 and 2 weeks after AMI were identified by multiple logistic regression analysis. Statistical analyses were performed with JMP ver. 9 (SAS Institute, Cary, NC, USA). A p value of 0.05 was considered significant.

Results

Patients’ clinical characteristics and laboratory values

Clinical characteristics of the study patients are shown in Table 1. Only HbA1c, fasting plasma glucose, 2-h OGTT glucose, HOMA-IR, eGFR, and the use of nitrate differed significantly between the two patient groups. Additional file 1 shows clinical characteristics of reference patients.
Table 1

Clinical characteristics of study patients upon enrollmenta, per study group

 

non-DM

DM

p valueb

 

n = 34

n = 34

Age (years)

62.1 ± 9.6

61.4 ± 9.9

0.739

Sex, male (%)

32 (94.1)

29 (85.3)

0.259

BMI

24.7 ± 2.5

25.3 ± 2.6

0.293

Risk factors

 Hypertension, n (%)

28 (82.4)

29 (85.3)

0.742

 Dyslipidemia, n (%)

26 (76.5)

26 (76.5)

1.000

 Smoking, n (%)

19 (55.9)

23 (67.6)

0.318

Biochemical markers

 HbA1c (%)

5.6 ± 0.3

6.6 ± 0.5

<0.001

 Fasting plasma glucose (mg/dL)

97.5 ± 7.4

114.6 ± 18.6

<0.001

 2 h OGTT plasma glucose (mg/dL)

119.8 ± 13.0

172.7 ± 33.7

<0.001

 HOMA-IR

1.53 ± 0.81

2.73 ± 1.89

<0.001

 eGFR (mL/min/1.73 m2)

63.2 ± 16.0

71.7 ± 16.5

0.035

 CPK (maximum) (U/L)

3532.2 ± 3898.3

2360.6 ± 2181.8

0.247

 hs-CRP (mg/dL)

0.654 ± 0.695

0.828 ± 0.712

0.311

 Total cholesterol (mg/dL)

199.9 ± 35.3

196.0 ± 57.4

0.954

 Triglyceride (mg/dL)

95.0 ± 55.2

127.6 ± 77.8

0.277

 HDL cholesterol (mg/dL)

46.6 ± 12.3

45.8 ± 10.0

0.825

 LDL cholesterol (mg/dL)

134.3 ± 29.5

116.7 ± 37.0

0.752

 NT-proBNP (pg/mL)

804.8 ± 1057.8

645.1 ± 915.0

0.578

Medications

 Ca channel blocker, n (%)

9 (26.5)

6 (17.6)

0.470

 Beta blocker, n (%)

19 (55.9)

18 (52.9)

0.924

 ACE-I/ARB, n (%)

22 (64.7)

25 (73.5)

0.504

 Nitrate, n (%)

30 (88.2)

18 (52.9)

0.004

 Statin, n (%)

24 (70.6)

23 (67.6)

0.853

aAt 1 week after AMI onset

Data are expressed as mean ± SD or number (%). bobtained by ANOVA or chi-square test. HbA1c, fasting plasma glucose, 2 h OGTT plasma glucose, HOMA-IR and eGFR levels were significantly higher and the use of nitrate was signifincatly lower in DM patients group.  DM diabetes mellitus, BMI body mass index, HbA1c hemoglobin A1c, OGTT oral glucose tolerance test, HOMA-IR homeostatic model assessment-insulin resistance, eGFR estimated glomerular filtration rate, CPK creatine phosphokinase, hs-CRP high-sensitivity C-reactive protein, HDL high density lipoprotein, LDL low density lipoprotein, NT-proBNP N-terminal prohormone of brain natriuretic peptide, ACE-I angiotensin converting enzyme inhibitor, ARB, angiotensin receptor blocker

Changes in oxidative stress

Shown in Fig. 1, the d-ROMs level 1 week after AMI did not differ significantly between the DM group and the non-DM group (463.1 ± 109.3 U.CARR vs. 475.4 ± 119.4 U.CARR, respectively, p = 0.382). At 2 weeks after AMI, the d-ROMs level had decreased significantly in the non-DM group (from 475.4 ± 119.4 U.CARR to 367.7 ± 87.9 U.CARR, p < 0.001) but remained unchanged in the DM group (from 463.1 ± 109.3 U.CARR to 461.7 ± 126.8 U.CARR, p = 0.819). Reference d-ROM values are shown in Additional file 2, the value in stable CAD patients without DM was 341.7 ± 101.7 U.CARR, and the value in those with DM was 377 ± 128.3 U.CARR. There was no signifincat difference between these values.

Major determinant of changes in oxidative stress

In the total patient group, significant positive correlation was found between d-ROMs levels 1 week after AMI and NT-proBNP levels (r = 0.376, p = 0.041) (Fig. 2, left panel) and between d-ROMs levels at 2 weeks and 2-h OGTT glucose levels (r = 0.434, p < 0.001) (Fig. 2, right panel). There was no relation between the d-ROMs level and age, sex, BMI, glucose profiles except 2-h OGTT glucose level, renal function, CPK, lipids, or use of the various medications. Multivariate logistic regression analysis showed the presence of DM to be a significant predictor of little or no change in the d-ROMs level by 2 weeks after AMI (Table 2), after adjustment for significant factors identified by univariate analysis (odds ratio: 3.33, 95 % confidence interval: 1.15–10.48) (Table 2).
Fig. 1

Change in the serum d-ROMs levels after AMI in patients with and without DM. d-ROMs, derivatives of reactive oxygen metabolites; AMI, acute myocardial infarction; DM, diabetes mellitus

Fig. 2

Correlation between d-ROMs levels and NT-proBNP levels at 1 week after AMI (left) and between d-ROMs levels at 2 weeks after AMI and glucose levels at 2 h after OGTT (right). d-ROMs, derivatives of reactive oxygen metabolites; AMI, acute myocardial infarction; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; OGTT, oral glucose tolerance test

Table 2

Factors tested as predictors of lack of change in the d-ROMs level 2 weeks after AMI

 

Univariate analysis

Multivariate analysis

Factor

OR (95 % CI)

p value

OR (95 % CI)

p value

Age

1.01 (0.95–1.07)

0.677

  

Sex

1.50 (0.31–10.87)

0.629

  

BMI

1.09 (0.89–1.35)

0.396

  

Diabetes mellitus

3.05 (1.07–9.34)

0.037

3.33 (1.15–10.48)

0.027

Fasting glucose level

1.01 (0.98–1.05)

0.363

  

2 h OGTT glucose level

1.02 (1.00–1.03)

0.032

1.02 (1.00–1.04)

0.098

HOMA-IR

1.10 (0.79–1.51)

0.570

  

eGFR

1.00 (0.98–1.04)

0.675

  

CPK (maximum)

1.00 (1.00–1.00)

0.354

  

LDL cholesterol

0.99 (0.97–1.01)

0.424

  

hs-CRP

1.05 (0.48–2.13)

0.904

  

NT-proBNP

1.00 (1.00–1.00)

0.147

  

Ca channel blocker

0.18 (0.01–1.11)

0.122

  

Beta blocker

3.35 (0.84–17.03)

0.105

  

ACE-I/ARB

0.38 (0.02–3.38)

0.428

  

Nitrate

0.20 (0.05–0.83)

0.028

0.36 (0.07–1.89)

0.216

Statin

0.39 (0.09–1.60)

0.180

  

Multivariate logistic regression analysis showed the presence of diabetes mellitus was a significant predictor of no change in the d-ROMs level by 2 weeks after AMI. d-ROMs derivatives of reactive oxygen metabolites, AMI acute myocardial infarction, OR odds ratio, CI confidence interval, BMI body mass index, OGTT oral glucose tolerance test, HOMA-IR homeostatic model assessment-insulin resistance, eGFR estimated glomerular filtration rate, CPK creatine phosphokinase, LDL low density lipoprotein, hs-CRP high-sensitivity C-reactive protein, NT-proBNP N-terminal prohormone of brain natriuretic peptide, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker

Discussion

Oxidative stress is implicated in various disorders and pathogeneses. Many studies have shown its involvement in the pathogeneses of lifestyle-related diseases. Previous clinical studies have made use of markers of ROS, such as 8-hydroxydeoxyguanosine and 8-iso-prostaglandin-F2α. However, it is difficult to measure these markers at health checkup facilities. Furthermore, superoxide dismutase, which can serve as an index of antioxidant potential, is also difficult to measure, even at research facilities. In this study, we used a simple assay method to examine the course of oxidative stress between 1 week and 2 weeks after AMI in patients with DM. This is the first study to observe time-specific change in oxidative stress in the early stage after AMI and to examine the difference in exposure to oxidative stress between patients with DM and those without DM.

Recent studies have shown the usefulness d-ROMs assay for evaluating oxidative stress [1315, 17], and in such evaluation, Trotti et al. found no statistically significant difference between male and female Europeans [11], whereas Fukui et al. found the mean d-ROMs level in female Japanese to be significantly higher than that in male Japanese [25]. Moreover positive correlation between levels of hs-CRP and d-ROMs has been reported [14, 15, 17]. Nevertheless, we found that most clinical characteristics, including sex and hs-CRP, are not factors that significantly influence d-ROMs in patients with AMI. However, we did find that the NT-proBNP level was a significant predictor of the d-ROMs level at 1 week after AMI. This is consistent with the previously reported correlation between BNP and post-MI remodeling [2628]. Furthermore, DM and hyperglycemia were identified as predictors of non-suppression of ROS production after AMI. Thus, it appears that the d-ROMs level at 1 week is influenced by the effect of MI on the heart itself, whereas the d-ROMs level at 2 weeks is the result of the continuous DM-induced hyperglycemia.

Continuous hyperglycemia increases production of AGEs and high levels of AGEs have been found in the cardiac tissue of diabetic patients [29]. AGEs induce oxidative stress and activate the protein kinase C/diacylglycerol signaling pathway, which is one of the mechanisms by which hyperglycemia exerts adverse cardiovascular effects. In addition, AGEs activate ROS production in mitochondria [20]. Increases in ROS cause cardiac dysfunction by directly damaging proteins and DNA and by inducing apoptosis [30]. We have reported a study in which we treated patients with alpha-glucosidase inhibitor (α-GI) from 1 week to 2 weeks after AMI [31]. In that study, we found that the d-ROMs level in patients treated with α-GI tended to decrease and that endothelial function improved. Thus, oxidative stress plays a pivotal role in the development of the microvascular and cardiovascular complications of DM.

There are some limitations to the present study. First, this was an association study using a case–control design and not randomized, however, the patient characteristics were well matched between groups (Table 1). Second, sample size was small and this was a single-center study. Therefore, we are not able to apply our result to the general population. Third, although we showed reference d-ROM values in stable CAD patients (Additional file 2: Table S1), this was a very short-term follow-up study, and because we did not record d-ROMs levels before AMI or primary PCI and after PCI or more than 2 weeks after AMI, any difference in d-ROMs levels after primary PCI and any progressive change in oxidative stress after AMI in patients with DM remain unknown. Fourth, we excluded patients with heart failure resulting from severe MI, first, because it has been reported that DM can lead to heart failure after MI, and second, because oxidative stress may be high in patients with heart failure [32, 33].

Conclusions

Our study showed that patients with DM are subject to clinically significant oxidative stress during the first 2 weeks after AMI. Although long-term changes in oxidative stress after AMI in patients with DM remain unknown, results of this short-term follow-up study imply that continuous hyperglycemia drives oxidative stress after AMI, leading to endothelial dysfunction, and progression of atherosclerosis.

Abbreviations

AGE: 

advanced glycation end product

AMI: 

acute myocardial infarction

CAD: 

coronary artery diesease

CPK: 

creatine phosphokinase

DM: 

diabetes mellitus

d-ROM: 

derivatives of reactive oxygen metabolite

eGFR: 

estimated glomerular filtration rate

HbA1c: 

hemoglobin A1c

HOMA-IR: 

homeostasis model assessment of insulin resistance

hs-CRP: 

high-sensitivity C-reactive protein

NT-proBNP: 

N-terminal prohormone of brain natriuretic peptide

OGTT: 

oral glucose tolerance test

PCI: 

percutaneous coronary intervenetion

ROS: 

reactive oxygen species.

α-GI: 

alpha-glucosidase inhibitor

Declarations

Acknowledgements

We sincerely thank all CCU staff at Nihon University Itabashi Hospital.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its Additional files 1 and 2.

Authors’ contributions

DK contributed to the study design, collected the data, and drafted the manuscript. KN, MA, and KO contributed to the study design and data collection. TT, TH, and AH contributed to the study design and reviewed and edited the manuscript. All authors critically reviewed the draft and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Division of Cardiology, Department of Medicine, Nihon University School of Medicine

References

  1. Aviram M. Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radic Res. 2000;33(Suppl):85–97.Google Scholar
  2. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation. 2003;108:2034–40.View ArticlePubMedGoogle Scholar
  3. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003;91:7A–11A.View ArticlePubMedGoogle Scholar
  4. Walter MF, Jacob RF, Jeffers B, Ghadanfar MM, Preston GM, Buch J, et al. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. J Am Coll Cardiol. 2004;44:1996–2002.View ArticlePubMedGoogle Scholar
  5. Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brümmer J, et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case–control study. Circulation. 2004;109:843–8.View ArticlePubMedGoogle Scholar
  6. Shimada K, Mokuno H, Matsunaga E, Miyazaki T, Sumiyoshi K, Miyauchi K, et al. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis. 2004;174:343–7.View ArticlePubMedGoogle Scholar
  7. Wu LL, Chiou CC, Chang PY, Wu JT. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta Int J Clin Chem. 2004;339:1–9.View ArticleGoogle Scholar
  8. Faraci FM, Didion SP. Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol. 2004;24:1367–73.View ArticlePubMedGoogle Scholar
  9. Pyne-Geithman GJ, Caudell DN, Prakash P, Clark JF. Glutathione peroxidase and subarachnoid hemorrhage: implications for the role of oxidative stress in cerebral vasospasm. Neurol Res. 2009;31:195–9.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Cesarone MR, Belcaro G, Carratelli M, Cornelli U, De Sanctis MT, Incandela L, et al. A simple test to monitor oxidative stress. Int Angiol. 1999;18:127–30.PubMedGoogle Scholar
  11. Trotti R, Carratelli M, Barbieri M. Performance and clinical application of a new, fast method for the detection of hydroperoxides in serum. Panminerva Med. 2002;44:37–40.PubMedGoogle Scholar
  12. Lubrano V, Vassalle C, L’Abbate A, Zucchelli GC. A new method to evaluate oxidative stress in humans. Immuno-Anal Biol Spéc. 2002;17:172–5.Google Scholar
  13. Atabek ME, Vatansev H, Erkul I. Oxidative stress in childhood obesity. J Pediatr Endocrinol Metab. 2004;17:1063–8.PubMedGoogle Scholar
  14. Kamezaki F, Yamashita K, Kubara T, Suzuki Y, Tanaka S, Kouzuma R, et al. Derivatives of reactive oxygen metabolites correlates with high-sensitivity C-reactive protein. J Atheroscler Thromb. 2008;15:206–12.View ArticlePubMedGoogle Scholar
  15. Sakane N, Fujiwara S, Sano Y, Domichi M, Tsuzaki K, Matsuoka Y, et al. Oxidative stress, inflammation, and atherosclerotic changes in retinal arteries in the Japanese population; results from the Mima study. Endocr J. 2008;55:485–8.View ArticlePubMedGoogle Scholar
  16. Pasquini A, Luchetti E, Marchetti V, Cardini G, Iorio EL. Analytical performances of d-ROMs test and BAP test in canine plasma. Definition of the normal range in healthy Labrador dogs. Vet Res Commun. 2008;32:137–43.View ArticlePubMedGoogle Scholar
  17. Hirose H, Kawabe H, Komiya N, Saito I. Relations between serum reactive oxygen metabolites (ROMs) and various inflammatory and metabolic parameters in a Japanese population. J Atheroscler Thromb. 2009;16:77–82.View ArticlePubMedGoogle Scholar
  18. Kotani K, Tsuzaki K, Taniguchi N, Sakane N. Correlation between reactive oxygen metabolites & atherosclerotic risk factors in patients with type 2 diabetes mellitus. Indian J Med Res. 2013;137:742–8.PubMedPubMed CentralGoogle Scholar
  19. Hirata Y, Yamamoto E, Tokitsu T, Kusaka H, Fujisue K, Kurokawa H, et al. Reactive oxygen metabolites are closely associated with the diagnosis and prognosis of coronary artery disease. J Am Heart Assoc. 2015;4:e001451.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Santilli F, Lapenna D, La Barba S, Davì G. Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus. Free Radic Biol Med. 2015;80:101–10.View ArticlePubMedGoogle Scholar
  21. Vazzana N, Santilli F, Sestili S, Cuccurullo C, Davi G. Determinants of increased cardiovascular disease in obesity and metabolic syndrome. Curr Med Chem. 2011;18:5267–80.View ArticlePubMedGoogle Scholar
  22. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–70.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Iamele L, Fiocchi R, Vernocchi A. Evaluation of an automated spectrophotometric assay for reactive oxygen metabolites in serum. Clin Chem Lab Med. 2002;40:673–6.View ArticlePubMedGoogle Scholar
  24. Palmieri B, Sblendorio V. Oxidative stress tests: overview on reliability and use. Part II. Eur Rev Med Pharmacol Sci. 2007;11:383–99.PubMedGoogle Scholar
  25. Fukui T, Yamauchi K, Maruyama M, Yasuda T, Kohno M, Abe Y. Significance of measuring oxidative stress in lifestyle-related diseases from the viewpoint of correlation between d-ROMs and BAP in Japanese subjects. Hypertens Res. 2011;34:1041–5.View ArticlePubMedGoogle Scholar
  26. Hirayama A, Yamamoto H, Sakata Y, Asakura M, Sakata Y, Fuji H, et al. Usefulness of plasma brain natriuretic peptide after acute myocardial infarction in predicting left ventricular dilatation six months later. Am J Cardiol. 2001;88:890–3.View ArticlePubMedGoogle Scholar
  27. Hirayama A, Kusuoka H, Yamamoto H, Sakata Y, Asakura M, Higuchi Y, et al. Serial changes in plasma brain natriuretic peptide concentration at the infarct and non-infarct sites in patients with left ventricular remodelling after myocardial infarction. Heart. 2005;91:1573–7.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Hirayama A, Kusuoka H, Yamamoto H, Sakata Y, Asakura M, Higuchi Y, et al. Usefulness of plasma brain natriuretic peptide concentration for predicting subsequent left ventricular remodeling after coronary angioplasty in patients with acute myocardial infarction. Am J Cardiol. 2006;98:453–7.View ArticlePubMedGoogle Scholar
  29. Willemsen S, Hartog JWL, Hummel YM, van Ruijven MH, van der Horst IC, van Veldhuisen DJ, et al. Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. Eur J Heart Fail. 2011;13:76–82.View ArticlePubMedGoogle Scholar
  30. Liu Q, Wang S, Cai L. Diabetic cardiomyopathy and its mechanisms: role of oxidative stress and damage. J Diabetes Investig. 2014;5:623–34.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Kitano D, Chiku M, Li Y, Okumura Y, Fukamachi D, Takayama T, et al. Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia. Cardiovasc Diabetol. 2013;12:92.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Von Bibra H, St John Sutton M. Impact of diabetes on postinfarction heart failure and left ventricular remodeling. Curr Heart Fail Rep. 2011;8:242–51.View ArticleGoogle Scholar
  33. Dennis KE, Hill S, Rose KL, Sampson UK, Hill MF. Augmented cardiac formation of oxidatively-induced carbonylated proteins accompanies the increased functional severity of post-myocardial infarction heart failure in the setting of type 1 diabetes mellitus. Cardiovasc Pathol. 2013;22:473–80.View ArticlePubMedGoogle Scholar

Copyright

© Kitano et al. 2016

Advertisement